DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice

被引：0

作者：

Matsumoto, G ^{[1
]}

Rahman, MA ^{[1
]}

Muta, M ^{[1
]}

Nakamura, T ^{[1
]}

Bando, H ^{[1
]}

Saji, S ^{[1
]}

Tsuruta, K ^{[1
]}

Okamoto, A ^{[1
]}

Toi, M ^{[1
]}

机构：

[1] Tokyo Metropolitan Komagome Hosp, Dept Surg, Bunkyo Ku, Tokyo 1138677, Japan

来源：

ONCOLOGY REPORTS | 2004年 / 12卷 / 02期

关键词：

cyclooxygenase-2; DFU; breast cancer;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cyclooxygenase-2 (COX-2) inhibitors are regarded as potentially important in strategies for cancer treatment. However, the precise mechanisms of these anti-inflammatory drugs as anti-cancer therapy are still unknown. In this study, we examined the effect of DFU both in vitro on MCF-7 cell growth, as well as in vivo on tumor growth produced by MCF-7 cell injection in mice. DFU has growth inhibitory effects on tumor growth in mice compared to the control group. We examined the tumor tissues for apoptosis and angiogenesis by immunostaining. Apoptosis was detected only in the treatment group. DFU treatment also resulted in the inhibition of angiogenesis, as well as decreased COX-2 expression. Results of this study suggest that inhibitory effects of DFU might be COX-2 dependent.

引用

页码：281 / 285

页数：5

共 50 条

[41] Idoxifene antagonism of oestradiol-dependent MCF-7 breast cancer xenograft growth
Johnston, SRD
Dowsett, M
Riddler, S
Jarman, M
EUROPEAN JOURNAL OF CANCER, 1998, 34 : S81 - S81
[42] Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor
Yamamoto, T
NozakiTaguchi, N
BRAIN RESEARCH, 1996, 739 (1-2) : 104 - 110
[43] Characterization of inhibited growth of cyclooxygenase-2 (COX-2) expressing human hepatoma cells by a selective COX-2 inhibitor (NS-398).
Hu, KQ
McCracken, J
Mineyama, Y
Yu, CH
Hillebrand, D
HEPATOLOGY, 2001, 34 (04) : 388A - 388A
[44] Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: Inhibition of tumor angiogenesis with extensive tumor necrosis
Kang, Khong Bee
Wang, Ting Ting
Woon, Chow Thai
Cheah, Elizabeth S.
Moore, Xiao Lei
Zhu, Congju
Wong, Meng Cheong
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (03): : 888 - 896
[45] N-Caffeoyl serotonin as selective COX-2 inhibitor
Takahashi, Toshiyuki
Miyazawa, Mitsuo
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (07) : 2494 - 2496
[46] L-745,337, A SELECTIVE COX-2 INHIBITOR
PRASIT, P
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 208 : 272 - MEDI
[47] Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor
Patrignani, P
Capone, ML
Tacconelli, S
EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (02) : 265 - 284
[48] Meloxicam, a selective COX-2 inhibitor, in the therapy of postoperaive pain
Loncar-Stojiljkovic, D
Stojiljkovic, MP
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (11) : A228 - A228
[49] The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis
Schiffmann, Susanne
Sandner, Jessica
Schmidt, Ronald
Birod, Kerstin
Wobst, Ivonne
Schmidt, Helmut
Angioni, Carlo
Geisslinger, Gerd
Groesch, Sabine
JOURNAL OF LIPID RESEARCH, 2009, 50 (01) : 32 - 40
[50] Lumiracoxib: More than just a selective COX-2 inhibitor
Castanda-Hernandez, Gilberto
Ortiz, Mario
Granados-Soto, Vinicio
ACTA PHARMACOLOGICA SINICA, 2006, 27 : 84 - 84

← 1 2 3 4 5 →